123018-62-2

Usage

Uses

Used in Pharmaceutical Industry:
4,4-Di-N-propylcyclohexanone is used as a key intermediate compound for the preparation of N-substituted phenylacetamide derivatives. These derivatives serve as therapeutic agents for the treatment of pain and inflammation, making them essential in the development of medications aimed at alleviating these conditions.

InChI:InChI=1/C12H22O/c1-3-7-12(8-4-2)9-5-11(13)6-10-12/h3-10H2,1-2H3

Upstream product

• 60729-41-1 4,4-dipropylcyclohex-2-en-1-one 

Downstream Products

• 913747-65-6 4,4-dipropylcyclohexanoneoxime 
• 1314090-60-2 N-(4,4-dipropyl-cyclohexylidene)-N'-pyridin-4-ylhydrazine 
• 130065-93-9 ethyl α-cyano-α-(4,4-dipropylcyclohexylidene)acetate 
• 123018-48-4 SKandF 106610 
• 123018-47-3 atiprimod 
• 123018-34-8 N,N-dimethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine dihydrochloride 
• 948552-26-9 Cyano-(1-cyano-4,4-dipropyl-cyclohexyl)-acetic acid ethyl ester 
• 130065-94-0 4,4-dipropyl-1-carboxycyclohexane-1-acetic acid 
• 123018-68-8 (1-Carboxymethyl-4,4-dipropyl-cyclohexyl)-acetic acid 
• 123018-64-4 4,4-dipropyl-1-carboxycyclohexane-1-acetic acid anhydride 

Relevant academic research and scientific papers

N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A compound represented by the formula: (I) wherein R1 represents a methoxy group, a hydroxyl group or a hydrogen atom; R2 represents a hydrogen atom, a C1-4 alkyl group, a C1-4 alkylcarbonyl group or an arylcarbonyl group; and D represents a group represented by the formula (A), (B) or (C) below. (A) (B) (C) This compound is useful as a therapeutic agent for a pain or inflammation induced by any one of various morbid conditions such as neuropathic pain, rheumatoid arthritis and osteoarthritis.

Immunomodulatory azaspiranes

A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an effective amount of an azaspirane derivative, a method of treating an animal in need of immunomodulation which comprises administering to such animal an effective amount of an azaspirane derivative, and certain azaspirane derivatives.

Antiarthritic and suppressor cell inducing activity of azaspiranes: Structure-function relationships of a novel class of immunomodulatory agents

Spirogermanium (1;8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decane-2-propanamin e dihydrochloride) is a potent cytotoxic agent in vitro which has demonstrated limited activity in experimental animal tumor models. Subsequently, it has been reported that spirogermanium has antiarthritic and suppressor cell-inducing activity. We have synthesized a series of substituted 8-hetero-2-azaspiro[4.5]decane and 9-hetero-3-azaspiro[5.5]undecane analogues of spirogermanium to identify the heteroatom requirements for in vivo antiarthritic and suppressor cell-inducing activity. This structure-activity relationship study has identified that appropriately substituted silicon and carbon analogues of spirogermanium retain both antiarthritic and immunosuppressive activity, with the 8,8-dipropyl (carbon) analogue being among the most active. Following the identification of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dihydrochloride (9) as more active analogue than spirogermanium, a series of 8,8-dipropyl analogues with various amine substituents were synthesized. A number of these analogues had activity similar to that of 9. A correlation between activity in the adjuvant arthritic rat and the ability to induce suppressor cells (r = 0.894, p0.001) suggests an association between the two pharmacologic effects. While the precise biochemical mechanism(s) for the pharmacological activity is unclear, these data suggest that compounds within this series, e.g., N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine dihydrochloride, may provide effective therapy in diseases of autoimmune origin and/or the prevention of rejection in tissue transplantation.